FACS
MCID: FTL073
MIFTS: 26

Fetal Anticonvulsant Syndrome (FACS)

Categories: Fetal diseases, Rare diseases

Aliases & Classifications for Fetal Anticonvulsant Syndrome

MalaCards integrated aliases for Fetal Anticonvulsant Syndrome:

Name: Fetal Anticonvulsant Syndrome 59
Fetal Antiepileptic Drug Syndrome 59
Fetal Aeds 59
Facs 59

Classifications:



External Ids:

ICD10 via Orphanet 34 Q86.8
UMLS via Orphanet 73 C1739111
Orphanet 59 ORPHA370068

Summaries for Fetal Anticonvulsant Syndrome

MalaCards based summary : Fetal Anticonvulsant Syndrome, also known as fetal antiepileptic drug syndrome, is related to fanconi anemia, complementation group c and fanconi anemia, complementation group a. An important gene associated with Fetal Anticonvulsant Syndrome is MTHFR (Methylenetetrahydrofolate Reductase). The drugs Glycerol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and t cells.

Related Diseases for Fetal Anticonvulsant Syndrome

Diseases related to Fetal Anticonvulsant Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 fanconi anemia, complementation group c 11.9
2 fanconi anemia, complementation group a 10.5
3 autosomal recessive disease 10.3
4 deficiency anemia 10.3
5 neutropenia 10.2
6 dentinogenesis imperfecta type 2 10.2
7 hair whorl 10.2
8 breast cancer 10.1
9 stomatitis 10.1
10 alopecia 10.1
11 neuroblastoma 1 10.1
12 immunodeficiency, common variable, 10 10.1
13 lymphocytic leukemia 10.1
14 leukemia 10.1
15 valproate embryopathy 10.0
16 myopia 10.0
17 autoimmune disease 10.0
18 leukemia, chronic lymphocytic 2 10.0
19 bladder cancer 10.0
20 colorectal cancer 10.0
21 leukemia, chronic lymphocytic 10.0
22 ovarian cancer 10.0
23 leukemia, acute myeloid 10.0
24 pachyonychia congenita 3 10.0
25 allergic hypersensitivity disease 10.0
26 dengue disease 10.0
27 sensory peripheral neuropathy 10.0
28 ischemia 10.0
29 embryonal carcinoma 10.0
30 pancreatic ductal adenocarcinoma 10.0
31 macular retinal edema 10.0
32 myeloid leukemia 10.0
33 diabetic macular edema 10.0
34 glioma 10.0
35 leukemia, b-cell, chronic 10.0
36 glial tumor 10.0
37 epicanthus 9.9
38 neural tube defects 9.9
39 strabismus 9.9
40 autism 9.9
41 astigmatism 9.9
42 asperger syndrome 9.9
43 autism spectrum disorder 9.9
44 suppression amblyopia 9.9
45 amblyopia 9.9
46 ametropic amblyopia 9.9
47 anisometropia 9.9
48 mechanical strabismus 9.9
49 color vision deficiency 9.9
50 alzheimer disease 9.8

Graphical network of the top 20 diseases related to Fetal Anticonvulsant Syndrome:



Diseases related to Fetal Anticonvulsant Syndrome

Symptoms & Phenotypes for Fetal Anticonvulsant Syndrome

Drugs & Therapeutics for Fetal Anticonvulsant Syndrome

Drugs for Fetal Anticonvulsant Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glycerol Approved, Investigational Phase 4 56-81-5 753
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Ticagrelor Approved Phase 4 274693-27-5 9871419
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Mycophenolic acid Approved Phase 4 24280-93-1 446541
8
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
11
Hydroxychloroquine Approved Phase 4 118-42-3 3652
12
Certolizumab pegol Approved Phase 4 428863-50-7
13 Antitubercular Agents Phase 4
14 Immunologic Factors Phase 4
15 insulin Phase 4
16 Insulin, Globin Zinc Phase 4
17 Vaccines Phase 4
18 Purinergic P2Y Receptor Antagonists Phase 4
19 Purinergic P2 Receptor Antagonists Phase 4
20 Platelet Aggregation Inhibitors Phase 4
21 Dopamine Agents Phase 4
22 Antiemetics Phase 4
23 Narcotics Phase 4
24 Central Nervous System Depressants Phase 4
25 Analgesics, Opioid Phase 4
26 Dopamine Antagonists Phase 4
27 Dopamine D2 Receptor Antagonists Phase 4
28 Autonomic Agents Phase 4
29 Soy Bean Phase 4
30 Hypoglycemic Agents Phase 4
31
s 1 (combination) Phase 4
32 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
33 Imatinib Mesylate Phase 4 220127-57-1 123596
34 Plerixafor octahydrochloride Phase 4
35
Tramadol Approved, Investigational Phase 2, Phase 3 27203-92-5 33741
36
Ketorolac Approved Phase 2, Phase 3 74103-06-3, 66635-83-4 3826
37
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
38
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
39
Clopidogrel Approved Phase 3 113665-84-2, 120202-66-6 60606
40
Atorvastatin Approved Phase 2, Phase 3 134523-00-5 60823
41 Coconut Approved Phase 3
42
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
43
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
44
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
45
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
46 Cyclooxygenase Inhibitors Phase 2, Phase 3
47 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
48 Ketorolac Tromethamine Phase 2, Phase 3
49
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
50 Astragalus Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 The Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Interven Tion Unknown status NCT02913469 Phase 4 Morphine;metoclopramide;saline
2 Fat, Inflammation and Insulin Resistance (FIRE-Study) Unknown status NCT01054989 Phase 4
3 Phase 4 Study: Comparison of Myfortic and Early Rapamycin Conversion vs. Low-Dose Tacrolimus in Preventing Acute Rejection and Chronic Allograft Fibrosis: A Protocol Biopsy Directed Approach Unknown status NCT00896012 Phase 4 Rapamune (sirolimus/rapamycin);Tacrolimus
4 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
5 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
6 Imatinib Mesylate Therapy in Systemic Mastocytosis Patients Lacking KIT Mutations Completed NCT01297777 Phase 4 Imatinib Mesylate
7 IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA Completed NCT02451748 Phase 4 Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg);Certolizumab pegol (CDP870, tradename Cimzia)
8 GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue. Not yet recruiting NCT02006225 Phase 4 Plerixafor
9 Comparison Between the Effects of Intravenous Morphine, Tramadol and Ketorolac on Stress and Immune Responses in Patients Undergoing Modified Radical Mastectomy Unknown status NCT02449954 Phase 2, Phase 3 Intravenous morphine sulphate;Intravenous tramadol HCL;Intravenous ketorolac tromethamine
10 Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy Unknown status NCT01802021 Phase 2, Phase 3 Astagalus-based Formula: Qingshu-Yiqi-Tang
11 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
12 Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome Completed NCT01774838 Phase 3 Prasugrel;Clopidogrel
13 HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease Completed NCT01100099 Phase 2, Phase 3
14 Determination of the Role of Oxygen on Mechanisms Involved in Ischemia-reperfusion Injury in Suspected Acute Myocardial Infarction by Biomarkers. A Sub Study to the DETO2X-AMI Trial. Completed NCT02290080 Phase 3 Oxygen
15 Randomised Controlled Trial to Evaluate the Effect of Statins on Asthma Control of Patients With Chronic Asthma Completed NCT00126048 Phase 2, Phase 3 Atorvastatin;Placebo
16 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
17 Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders Unknown status NCT01540292 Phase 1, Phase 2
18 A Randomised Controlled Trial of Combinating an Immune Modulator Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke Unknown status NCT02956200 Phase 2 Fingolimod
19 Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases Unknown status NCT01818713 Phase 2 2B3-101
20 New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis: Immunostimulation Plus Antibiotic Versus Immunosuppression Plus Antibiotic Versus Conventional Standardtherapy Unknown status NCT00244179 Phase 2 interferon-gamma;infliximab;dmard
21 Treatment With AMD3100 Added to a Mobilizing Regimen of G-CSF to Increase the Number of Peripheral Blood Stem Cells in Patients With Hodgkin's Disease Completed NCT00396201 Phase 2 G-CSF Plus Plerixafor
22 A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII Completed NCT00643097 Phase 2 Temozolomide
23 Study of Immune Responses and Safety of Recombinant CD40 Ligand in Patients With X-Linked Hyper IgM Syndrome Completed NCT00001145 Phase 2 Bacteriophage;rhuCD40L;KLH
24 Phase II Study Using a Myeloablative Lymphocyte Depleting Regimen of Chemotherapy and Intensive Total Body Irradiation Followed by Infusion of Tumor Reactive Lymphocytes and Reconstitution With CD34+ Stem Cells in Metastatic Melanoma Completed NCT00314106 Phase 2 Cyclophosphamide;Fludarabine
25 Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin Completed NCT00665470 Phase 2 Aldesleukin
26 A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia Completed NCT00001941 Phase 1, Phase 2
27 Phase I/II Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma Completed NCT00306969 Phase 1, Phase 2 bexarotene
28 Autologous Immunomagnetic Selected cd133+ Cells in the Treatment of No-option Critical Limb Ischemia: Clinical and Ceus Assessed Results. Completed NCT01595776 Phase 1, Phase 2
29 Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease Recruiting NCT00923013 Phase 2 Cladribine;Rituximab
30 A Phase II Study Using Talimogene Laherparepvec for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence Recruiting NCT02658812 Phase 2
31 Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
32 SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN as First Line Treatment of Advanced Soft Tissue Sarcoma (STS) Recruiting NCT03138161 Phase 1, Phase 2 Trabectedin;Ipilimumab;Nivolumab
33 Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Recruiting NCT01059786 Phase 2 Pentostatin;Rituximab;Bendamustine
34 Donor Regulatory T Cells (Treg) Infusion (DTI) in Patients With Steroid-refractory Chronic Graft-versus-host Disease (GVHD) Recruiting NCT01903473 Phase 2 Rapamycin
35 Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes Recruiting NCT03085771 Phase 2 desferal;Isotonic saline
36 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Active, not recruiting NCT00924170 Phase 1, Phase 2 LMB-2;Fludarabine;Cyclophosphamide
37 Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage II/IIIa NSCLC Not yet recruiting NCT03694236 Phase 1, Phase 2 durvalumab
38 A Phase II Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanoma Terminated NCT00863330 Phase 2
39 A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Terminated NCT02111863 Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
40 Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of MART-1 Reactive Peripheral Blood Lymphocytes (PBL) With or Without High Dose Aldesleukin Terminated NCT01495572 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin;MART-1 Reactive CD8+ PBL
41 Phase I/II Study Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Allogeneic Tumor-Reactive Lymphocyte Cell Line DMF5 in Metastatic Melanoma Terminated NCT00924001 Phase 1, Phase 2 DMF5 Melanoma Reactive TIL;Cyclophosphamide;Fludarabine;Aldesleukin
42 Phase I/II: Treatment of Adenovirus and Cytomegalovirus Infection Post Human Allogeneic Stem Cell Transplantation With Short-term Expanded Virus-specific T Cells Withdrawn NCT02702427 Phase 1, Phase 2
43 The Effect of Autologous Adipose Mesenchymal Stem Cells in Treatment of Airway Injury in Patients Exposed to Sulfur Mustard Unknown status NCT02749448 Phase 1
44 Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patents With Metastatic Breast Cancer Completed NCT00849459 Phase 1
45 Leukine (Sargramostim) for Parkinson's Disease Completed NCT01882010 Phase 1 sargramostim;placebo
46 Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease Completed NCT00774982 Phase 1 Delayed Release 6 mercaptopurine;6 Mercaptopurine
47 A Phase I Study Using Vaccination With NY-ESO-1 Recombinant Protein Mixed With CpG7909 and Montanide® ISA-51 in Patients With Cancers That Often Express NY-ESO-1. Completed NCT00299728 Phase 1
48 A PHASE I, OPEN LABEL, DOSE-ESCALATION TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF EF-022 (MODIFIED VITAMIN D BINDING PROTEIN MACROPHAGE ACTIVATOR) IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES Completed NCT02052492 Phase 1 EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
49 An Open Label Study to Evaluate Innate Immune Responses Induced by a Pattern Recognition Receptor Agonist, Poly-ICLC (Hiltonol), in Healthy Volunteers Completed NCT01299662 Phase 1 Poly ICLC
50 A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer Recruiting NCT02599454 Phase 1 Atezolizumab

Search NIH Clinical Center for Fetal Anticonvulsant Syndrome

Genetic Tests for Fetal Anticonvulsant Syndrome

Anatomical Context for Fetal Anticonvulsant Syndrome

MalaCards organs/tissues related to Fetal Anticonvulsant Syndrome:

41
Breast, Lung, T Cells, Bone, Neutrophil, Myeloid, Monocytes

Publications for Fetal Anticonvulsant Syndrome

Articles related to Fetal Anticonvulsant Syndrome:

(show all 20)
# Title Authors PMID Year
1
Fetal valproate syndrome: the Irish experience. 38
29396778 2018
2
Development of a core outcome set for epilepsy in pregnancy (E-CORE): a national multi-stakeholder modified Delphi consensus study. 38
27860117 2017
3
Early valproic acid exposure alters functional organization in the primary visual cortex. 38
21215743 2011
4
Intracranial arteriovenous malformation with maternal carbamazepine use. 38
17264463 2007
5
Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes. 38
16239295 2006
6
A case of fetal anticonvulsant syndrome with severe bilateral upper limb defect. 38
16676441 2006
7
Characteristics of fetal anticonvulsant syndrome associated autistic disorder. 38
16108456 2005
8
Using current evidence in selecting antiepileptic drugs for use during pregnancy. 38
16059433 2005
9
Interaction between anticonvulsants and human placental carnitine transporter. 38
15009220 2004
10
The importance of monotherapy in pregnancy. 38
12796519 2003
11
Pregnancy in the woman with epilepsy: maternal and fetal outcomes. 38
12528055 2002
12
Ophthalmic findings in fetal anticonvulsant syndrome(s). 38
11986102 2002
13
A clinical study of 57 children with fetal anticonvulsant syndromes. 38
10882750 2000
14
5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. 38
10791559 2000
15
Developing diagnostic criteria for the fetal anticonvulsant syndromes. 38
10775521 2000
16
Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. 38
10563481 1999
17
Fetal anticonvulsant syndrome in rats: effects on postnatal behavior and brain amino acid content. 38
4080065 1985
18
Functional palatal incompetence in the fetal anticonvulsant syndrome. 38
6497436 1984
19
Fetal anticonvulsant syndrome in rats: dose- and period-response relationships of prenatal diphenylhydantoin, trimethadione and phenobarbital exposure on the structural and functional development of the offspring. 38
6195326 1983
20
[Pharmacotherapy of epilepsy--current problems and controversies]. 38
6418628 1983

Variations for Fetal Anticonvulsant Syndrome

Expression for Fetal Anticonvulsant Syndrome

Search GEO for disease gene expression data for Fetal Anticonvulsant Syndrome.

Pathways for Fetal Anticonvulsant Syndrome

GO Terms for Fetal Anticonvulsant Syndrome

Sources for Fetal Anticonvulsant Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....